Adlai Nortye Ltd.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Yang Lu
- Full Time Employees
- 123
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Ugland House Grand Cayman Cayman Islands KY1-1104
- IPO Date
- Sep 29, 2023
- CIK
- 0001944552
- Website
- adlainortye.com
- Similar Companies
- Business
- Adlai Nortye Ltd. is a global clinical-stage biopharmaceutical company specializing in the discovery and development of innovative targeted and immune-modulating cancer therapies. Founded in 2016 and headquartered in Hangzhou, China, with global R&D centers in the United States and China, the company advances a robust oncology pipeline including AN8025, a trifunctional fusion protein modulating T cells and antigen-presenting cells; AN9025, an oral small molecule pan-RAS(ON) inhibitor targeting a broad spectrum of RAS mutations; AN4005, an oral PD-L1 inhibitor; and AN2025 (Buparlisib), a pan-PI3K inhibitor in a registrational Phase 3 trial for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The company also develops AN0025 (Palupiprant) and AN4035 (a CEACAM5 antibody-drug conjugate). Adlai Nortye operates as an investment holding company incorporated in the Cayman Islands. In recent developments, Adlai Nortye expanded its technical and commercial partnership with Xiamen Biotime Biotechnology Co., Ltd. to facilitate the global development and commercialization of oncology products, including AN4005 and AN3025. The company appointed Roger Sawhney, M.D. to its Board of Directors in 2024 and named Tse M.D., Ph.D. as Head of Research and Development, bolstering leadership expertise. In 2024, clinical trial advancements included promising safety and efficacy results for AN4005, with a complete response reported, and plans to report Phase 3 overall survival data for buparlisib in early 2025. The company bolstered its financial position with $98 million in cash as of mid-2024, supporting ongoing R&D and operations. Adlai Nortye targets oncology patients globally with a focus on developing novel immuno-oncology and targeted therapies across a range of solid tumors and hematologic malignancies. The company maintains strategic research collaborations and clinical operations spanning the U.S. and China to drive innovation and regulatory milestone achievements for its pipeline candidates. The enterprise emphasizes advancing differentiated novel molecules with potential first- or best-in-class profiles aimed at transforming cancer treatment paradigms. This profile encapsulates Adlai Nortye’s comprehensive product portfolio, key strategic partnerships, leadership appointments, clinical trial progression, and financial health, reflecting its position as an emerging player in the global oncology biopharmaceutical sector.
Adlai Nortye Ltd. Sponsored ADR (ANL) Upgraded to Buy: Here's What You Should Know
Here's Why Adlai Nortye Ltd. Sponsored ADR (ANL) Is a Great 'Buy the Bottom' Stock Now
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?
Adlai Nortye Announces $150.0 Million Private Placement Equity Financing
Adlai Nortye Ltd. Sponsored ADR (ANL) Upgraded to Buy: Here's Why
Is Adlai Nortye Ltd. Sponsored ADR (ANL) Outperforming Other Medical Stocks This Year?
Has Adlai Nortye Ltd. Sponsored ADR (ANL) Outpaced Other Medical Stocks This Year?
Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations
Adlai Nortye Announces $140.0 Million Private Placement Equity Financing
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Sees Large Decrease in Short Interest
Financial Comparison: Adlai Nortye (NASDAQ:ANL) vs. Pharming Group (NASDAQ:PHAR)
Morning Market Pulse: Defense-to-Data Bets, Capital Raises, and AI-Powered Platforms Shape the Open
Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Short Interest Update
Adlai Nortye (NASDAQ:ANL) Shares Down 1.4% – Here’s Why
Adlai Nortye to Present Short Talk at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Adlai Nortye Ltd. Announces Topline Results of Phase III Buran Trial Evaluating Buparlisib in Combination with Paclitaxel for Recurrent or Metastatic HNSCC
Adlai Nortye Ltd. Sponsored ADR (ANL) Loses -33.06% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024
Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy